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For centuries, zeolites have been used for their utility in binding metals, and
they feature in a multitude of agricultural and industrial applications in which
the honeycombed zeolite structures form ideal ion exchangers, catalysts and
binding agents. Zeolites are currently in a transition period, moving towards
implementation in human ailments and diseases. Here, we postulated that
zeolites may be able to counter the effects of excess iron and conducted a
mouse model trial to gauge the utility of this notion. We used the transgenic
mouse strain MexTAg299 for a thirty-week pilot trial in which iron polymal-
tose and/or the zeolite clinoptilolite was injected into the peritoneum twice
weekly. Mice were sacrificed at the end of the trial period and examined by
postmortem and histology for significant physiological differences between
mouse subgroups. In this study, we demonstrated that a common zeolite,
clinoptilolite, is able to maintain the general health and well-being of mice
and prevent iron-induced deleterious effects following iron overload. When
zeolites are given with iron biweekly as intraperitoneal injections, mice
showed far less macroscopic visual organ discoloration, along with near nor-
mal histology, under iron overload conditions when compared to mice
injected with iron only. The purpose of the present pilot study was to examine
potential alternatives to current iron chelation treatments, and the results
indicate an advantage to using zeolites in conditions of iron excess. Zeolites
may have translational potential for use in cases of human iron overload.
Iron overload disorders in humans are manifest mainly
as hereditary (primary) hemochromatosis [1,2], which
results mostly in an accumulation of iron in the forms
of ferritin and hemosiderin, which cause solid organ
injury, particularly to the liver, heart or pancreas. It is
the most common genetic disorder in Caucasians.
Hereditary hemochromatosis may lead to pathological
conditions, including cirrhosis, weight loss, chronic
fatigue, liver disease, hepatocellular carcinoma, joint
pain, diabetes and cardiomyopathy [3,4].
Iron overload has been studied extensively in
humans and in many animal models of iron-induced
cancer [5,6]. In one trial [7], male Wistar rats were
injected (intraperitoneal) with iron saccharate daily for
5 months and sacrificed 1 year later. Nine of 19 rats
had mesothelioma tumours upon postmortem exami-
nation, leading the authors to conclude that the grad-
ual release of free iron could induce mesotheliomas.
This and other animal model studies [5] have identified
iron-induced free radical generation, lipid peroxida-
tion, DNA damage and carcinogenesis.
Iron is the most abundant metal in the human body
and is mostly benignly bound to haemoglobin and
other proteins. In excess, or when introduced extrane-
ously, it generates hydroxide radicals and pathways to
carcinogenesis [8]. A US epidemiological study
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published in 2008 for peripheral arterial disease
patients, phlebotomy twice a year reduced the inci-
dence of visceral cancer by 35% and cancer mortality
by 61% in a randomized trial using 1277 patients. The
consequences of the introduction of excessive quanti-
ties of iron sugar polymer composites have been the
subject of repeated investigations [5,6,9]. These studies
focussed chiefly on iron overload disorders in humans
and in particular hemochromatosis.
Zeolites have been used for centuries for their utility
in binding metals and in many agricultural and indus-
trial processes in which the honeycombed zeolite struc-
tures are ideal as ion exchangers, catalysts and binding
agents. They are useful as feed supplements and are in
a transition period of application to human ailments
and diseases. Zeolites are hydrated aluminosilicate vol-
canic minerals that are rare in nature in being nega-
tively charged. Most zeolites have cubic spheroidal
shapes with porous internal spaces or cages that are
able to adsorb and sequester and neutralize positively
charged ions [10]. They are ideally suited to adsorbing
heavy metals and small organic toxins and have been
used for decades in industrial, agricultural and house-
hold processes [11]. Naturally occurring zeolites, includ-
ing clinoptilolite and mordenite, have been shown to be
biological benign [12–14], with mordenite eliciting only
minor fibrosis and inflammation in rodents [15]. The
US FDA has classified zeolites as GRAS (Generally
Regarded As Safe), with the sole exception of erionite,
which is toxic. It is not clear why erionite is toxic, with
the most likely reason being its fibrous shape at the
micrometre level, making it more closely resemble
asbestos.
In this novel pilot mouse model study, we demon-
strated adverse effects of iron given as intraperitoneal
injections twice weekly to a transgenic mouse strain,
and the moderation of these effects by the common
zeolite, clinoptilolite. The beneficial effects of the zeo-
lite cotreatment point to the potential for its use in
iron overload disorders and to a wider spectrum of
uses, including asbestos-related diseases in which the
release of iron is a major causal link.
Materials and methods
Preparation of materials
Clinoptilolite, a crystalline aluminosilicate zeolite mineral, was
obtained from St Cloud Mining Co (NM, USA). Its empirical
formula is (K,Ca,Mg) 2O-AL2O3-10SiO2-6H2O. The cation
exchange capacity is 0.8–1.2 meqg1, and it is 98% pure by
analysis (University of Alberta), but may contain 0.07–0.10%
free silica. Over 80% of the particles have diameters of 13.0–
25.4 mm. The powder was made into a suspension (1 g zeo-
lite to 1.5 mL water in a 5-mL capacity grinding bowl with
two zircon balls) and milled in a Fritsch Pulverisette 23 for 5
mins. The milled particles were analysed in a Malvern Master-
sizer 2000. The median particle size was estimated at 4.28 lm
from the particle distribution as illustrated in Fig. 1 (left plot).
Chabazite, another zeolite, was milled to a median particle
size of 5.50 lm (Fig. 1; right plot). Both milled zeolites had
over 80% of the particles in the range of 2 to 13 lm.
Iron-binding capacity of zeolites
Atomic absorption spectrometry (AAS) was used to mea-
sure the ability of the zeolites, clinoptilolite or chabazite, to
Fig. 1. Clinoptilolite (yellow) and chabazite (orange) particle size distributions after milling. The median particle sizes are 4.28 and 5.5 lm, respectively.
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chelate iron in a cell-free format. Iron as FeCl3 was diluted
in water to a final concentration of 50 lM and zeolites to
final concentrations of 1–10 mgmL1. Solutions or suspen-
sions of ferric chloride standards and clinoptilolite were
prepared in sterile deionized water. Samples (n = 5) of fer-
ric chloride and clinoptilolite or chabazite were mixed in
sealed tubes and placed on a rocking platform for 24 h.
Samples were then centrifuged to remove iron–clinoptilolite
complexes, and the supernatants were aspirated to fresh
tubes and analysed for [Fe3+] in an atomic absorption
spectrophotometer along with [Fe3+] standards.
Mice
The transgenic mouse strain MexTAg299 h [16] was devel-
oped at the School of Medicine & Pharmacology & Wes-
tern Australian Institute for Medical Research, University
of Western Australia. This strain was selected for this iron
trial, as a prelude to planned asbestos trials with the same
strain. The trial was conducted under guidelines set by the
Institutional Animal Care & Ethics Committee, with
defined humane endpoints. However, none of the mice
reached an endpoint that required euthanasia over the
30 weeks of the trial, but at its conclusion, all mice were
euthanized with carbon dioxide.
Targeted expression of the TAg transgene causes
mesothelioma to develop more rapidly after asbestos expo-
sure with 100% incidence within 20 to 40 weeks in Mex-
TAg mice compared to 30% incidence in wild-type mice in
50 to 100 weeks. MexTAg transgenic mice express the
SV40 large T antigen specifically in mesothelial cells by use
of the cell type-specific mesothelin promoter. MexTAg mice
exposed to asbestos develop cancer that faithfully replicates
key features of the pathogenesis of human mesothelioma
[17].
Injection protocol and trial parameters
Iron polymaltose (Ferrosig) and clinoptilolite (St Cloud
Mining Co, NM, USA) were prepared in sterile saline
(0.9%) for intraperitoneal injection at dosages of 15
mgkg1 and 45 mgkg1, respectively, and at 10 mLkg1.
Mice were injected twice weekly with normal saline (con-
trol), iron polymaltose (hereafter abbreviated to iron),
clinoptilolite or iron + clinoptilolite (Table 1). For the
combined injection of iron + clinoptilolite, working solu-
tions of each were prepared separately in saline and mixed
in the syringe just prior to peritoneal injection. This proto-
col was considered more suitable than separate injections
of iron and clinoptilolite in the combined treatment mouse
subgroup, as only half as many injections were required
over the trial period and this was less stressful to the well-
being of the mice. In addition, the iron was complexed as
iron polymaltose and therefore would not be immediately
bioavailable for sequestration by clinoptilolite [18]. The
concentration of iron for injection was similar to that used
in other mouse and rat trials [5,6]. The clinoptilolite con-
centration was chosen somewhat arbitrarily at threefold
higher than the iron concentration, but well below amounts
used (300 mgkg1) in mouse and dog trials that have





Liver Spleen Peritoneum Other Comments
xa01:f 21.5 Saline Slightly pale
xa02:f 21 Saline
xa03:f 22 Saline
xa04:m 28 Fe Enlarged Yellow/orange Less active
xa05:m 27.2 Fe Enlarged Protruding Yellow/orange Nodule (abdominal wall)
xa06:m 24 Fe Very enlarged Yellow/orange Less active
xa07:m 27.6 Fe Enlarged Orange Less active
xa08:f 19 Fe Enlarged Yellow/orange
xa09:f 17.4 Fe Slightly enlarged Yellow/orange Small nodule (mesentery)
xa10:f 19.8 Fe Enlarged Enlarged Yellow/orange Less active
xb01:f 17.1 Zeolite Slightly enlarged Enlarged Zeolite deposit
xb02:f 21.8 Zeolite Zeolite deposit
xb03:f 20.1 Zeolite Slightly pale Zeolite deposit Zeolite deposit Zeolite deposit
xb04:m 23.2 Zeolite + Fe Zeolite deposit
xb05:m 22.5 Zeolite + Fe Zeolite deposit
xb06:m 27 Zeolite + Fe Pale yellow
xb07:f 19.5 Zeolite + Fe Zeolite deposit
xb08:f 19.5 Zeolite + Fe Zeolite deposit Zeolite deposit
xb09:f 17.3 Zeolite + Fe Zeolite deposit
xb10:f 20.3 Zeolite + Fe Zeolite deposit
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shown no deleterious effects over a similar trial period
[19,20].
A total of 20 MexTAg299 h mice were used in the trial
(Table 1), three each as controls (saline or clinoptilolite)
and seven each for iron and iron + clinoptilolite injections.
The mice were of mixed gender with some siblings and
were 65–90 days old when received. They were fed a basal
diet and given water ad libitum. After a one-week acclimati-
zation, twice-weekly injections of saline, clinoptilolite, iron
polymaltose, and iron polymaltose and clinoptilolite were
given intraperitoneal and the mice were weighed and
observed for well-being or illness on a daily basis. The
duration of the trial was 30 weeks. Institutional ethics and
biosafety approvals were given ahead of the trial.
Postmortem
Visual examinations of the gut cavities and tissues and
organs were made and recorded. Organ samples were taken
for histological staining. A full summary of the postmortem
observations is given in Table 1.
Histology
Sectioned tissues were stained routinely with haematoxylin
and eosin (H&E) or Prussian blue. The latter stain was
used to identify iron within liver stellate macrophages
(Kupffer cells) that forms part of the mononuclear phago-
cyte system. These sections were taken from the outer edges
of the liver. The liver tissues were fixed, sectioned and
stained immediately after autopsy. For each section from
the iron- and iron + zeolite treated mice, ten consecutive
fields were chosen to count Kupffer cells with iron deposits.
All cells characterized were identified as Kupffer cells by
morphology, and although hepatocytes were also present in
the sections, these were clearly of different morphology.
Statistics
Statistical analysis was performed using SPSS 19.0 and
GraphPad Prism 7.0a software. The unpaired t-test or two-
way ANOVA used to analyse differences in the mouse
trials for organ cell counts and body weight changes over
time.
Results and Discussion
Natural clinoptilolite was used in this study. Another
natural zeolite, chabazite, was included in the initial
stages for comparison of milling and iron-binding
capacity. The two zeolites were milled to mean particle
sizes of 5.7 and 5.5 lm, respectively (Fig. 1), which we
determined to be ideal, in being large enough to pre-
vent most particulates crossing cell membranes, but
small enough to minimize innocuous aggregation and
immobility.
The iron-binding capacities of clinoptilolite and cha-
bazite were determined by AAS (Fig. 2). The results
plotted in Fig. 2 show that the milled zeolites were
able to absorb/chelate large amounts of free iron from
solution, a fact already known [10], but that was still
required to validate the zeolites for this study. Chaba-
zite adsorbed marginally more iron than clinoptilolite
in the concentration range used. Although not directly
applicable to the mouse trial in this study, it was
expected that the injected clinoptilolite would absorb
much of the free iron from the iron polymaltose injec-
tions in the subsequent mouse model trial.
The mouse model trial was set up for 30 weeks of
duration using four subgroups of the MexTAg299 h
transgenic strain, to be injected intraperitoneal twice
weekly with saline, iron, clinoptilolite or iron + clinop-
tilolite (Table 1). Postmortem macroscopic observa-
tions of the mice were different, in that the mice
injected with saline, zeolite or iron + zeolite looked
normal in coloration (Fig. 3A–C), whereas mice
injected with iron showed the gut and organs to be sig-
nificantly yellow/orange in coloration, especially in the
lower abdomen (Fig. 3D,E). These representative pho-
tographs were typical of all mice within the four sub-
groups, with the sole exception that one of the
iron + zeolite mice had a slightly yellowish coloration
in the lower abdomen cavity. Our conclusions were
that the coloration was due to the deposition and
therefore lack of clearance of iron. In contrast, in the
iron + zeolite mice, much of the iron was sequestered
as inert or innocuous within the zeolite particles, based
on the fact that there was no orange coloration of the
Fig. 2. Iron-binding capacity of clinoptilolite and chabazite in vitro.
Suspensions of clinoptilolite or chabazite in 50 lM FeCl3 solution
were mixed for 24 hrs, and residual [Fe3+] was measured by
atomic absorption against the iron solution as control (50 lM;
leftmost column). The three concentrations of the zeolites were
0.3, 1.0 and 3.0 mgmL1 in water. Free iron was measured from
a standard curve. The plotted vertical bars in the figure represent
the means of five samples (n = 5); and errors as SD.
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abdominal cavity in the macroscopic postmortem
examinations of the iron + zeolite mice. Further evi-
dence for this was derived from the histology (see
below).
A more detailed macroscopic examination revealed
further features of the effects of iron on the abdominal
organs (Table 1). In the mice injected with iron, all
showed enlarged livers and two of seven mice had
enlarged spleens. None of the control or iron + zeolite
mice showed any enlargement of organs visible to the
naked eye (Table 1). There were some zeolite aggre-
gates within the abdominal cavity, but there was no
evidence that these deposits affected the well-being of
the mice, which is in keeping from the results of earlier
studies in which mice were given intraperitoneal injec-
tions of ten times higher amounts of clinoptilolite with
no adverse behavioural effects in the mice [20,21].
Four of the seven iron-treated mice were noticeably
less active in the latter third of the trial than all other
mice. Two of the iron subgroup had small nodules in
the abdomen and these were surmised to be granulo-
mas rather than tumours, in view of these mice not
showing any of the telltale symptoms of tumour
growth, notably as marked physical changes in appear-
ance or behaviour, or abdominal tumours and/or
blood-stained ascites fluid. These observations are in
keeping with previous iron overload mouse or rat
studies have shown that tumours are rarely seen inside
12 months [22,23], whereas the appearance of granu-
loma nodules was more common. A similar outcome
was observed in a large and long-term (2.5 years) rat
trial in which cellulose fibres were injected at regular
intervals into the peritoneal cavity [24]. Only 14 of 200
rats developed malignant tumours and none earlier
than 18 months, whereas many granulomas and
fibrous adhesions were detected in many of the rats.
A comparison of the mouse weights across the trial
showed no significant difference among female mice
injected with iron only or with iron plus clinoptilolite
(Fig. 4A), but there was a significant difference for the
same treatments in male mice (Fig. 4B), where lower
body weights were registered almost from the start of
the trial to its completion in the iron only subgroup.
We surmise that the gender differences are real in
terms of the lower body weights of male versus female
mice treated with iron alone, based on previous obser-
vations that female mice are more tolerant of iron
overload [25,26]. In contrast to the iron subgroups,
there were virtually no differences in body weights of
males versus females in the iron plus clinoptilolite sub-
groups. This result is supported by the postmortem
examinations and histology (Table 1; Figs 3 and 5),
which showed little, if any, differences between male
and female mice treated with iron plus clinoptilolite.
Lastly, a clinoptilolite control subgroup of three
female mice showed body weights near those of the
doubly treated male and female mice subgroups (not
shown).
There was a small significant difference between the
zeolite + iron and female + iron subgroups
(P = 0.0013). All other pairings were significantly dif-
ferent (P < 0.0001). Interestingly, the female + iron
and male + iron groups were at opposite ends of the
body weight gain plots, with the zeolite control and
zeolite + iron plots between the other two. It does
seem that the female mice (collectively) were beginning
to gain more weight than normal, which might have
been more pronounced were the trial to have run
longer. On the other hand, the iron-treated male sub-
group showed marked and significant differences in
weight gains to all other subgroups (Fig. 4; red trace).
This trend may be explained by observations elsewhere
A B C D E
Fig. 3. Postmortem examination of the abdominal cavities of mice representative of each subgroup. Order is as follows: (A) saline; (B)
zeolite; (C) zeolite plus iron; (D) iron (male); (E) iron (female).
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that male mice and rats are much more susceptible
than are females to cancer induction by iron com-
plexes; and the incidence of cancer is paralleled by
increased lipid peroxidation. The hormonal environ-
ment is responsible for this sensitivity [5]. In summary,
the weight gain trends cannot be taken alone as indica-
tors of the iron overload and zeolite effects, but their
significance becomes more pronounced when the other
parameters (postmortems and histology) are included.
The liver histology supported the earlier data.
Although Kupffer cells may migrate within the liver,
they are sensitive to harmful or toxic agents such as
iron, and this results in the localization of more of the
Kupffer cells in the outer liver peritoneal layer, where
we took sections for haematoxylin and eosin (H&E)
and Prussian blue staining. The H&E-stained sections
show normal cellular physiology from the liver peri-
toneum of saline, zeolite and iron + zeolite mice
(Fig. 5A,B,C), but clear differences in the tissue from
the iron subgroup, in which the liver cells depict swel-
ling and disorganization (Fig. 5D). The Prussian blue
stain was used to identify iron particles within liver
stellate macrophages (Kupffer cells) that forms part of
the mononuclear phagocyte system. Here, it is clear
that the iron-treated mice retained more iron aggre-
gates in liver cells (Fig. 5H) than did cells from the
iron + zeolite treated mice (Fig. 5G). Although only
single sections are depicted, similar histology was
observed in all mice in each subgroup. Saline and zeo-
lite liver sections were also stained with Prussian blue,
but there was no visible iron staining (Fig. 5E,F).
All control mice (saline or clinoptilolite) and the
iron + zeolite subgroup appeared normal to the end of
the trial, and postmortem and histology confirmed that
the tissues and cell morphology were essentially indis-
tinguishable. However, there were clear differences
between these mice and the seven iron-treated mice,
Fig. 4. Body weight changes over time in female and male mice
injected intraperitoneal with iron only (blue traces; n = 3) or iron
plus clinoptilolite (black traces; n = 4 female, n = 3, male). The
differences between the iron and iron plus clinoptilolite treatments
are only significant for the male body weight traces (P < 0.0001). A
control trace for female mice (n = 3) treated with clinoptilolite
alone is not shown, but it is approximately similar to the black
trace in (A). All errors as SD.
BA DC
FE HG
Fig. 5. Histology of liver sections. Top and bottom plates are H&E and Prussian blue stained, respectively. Saline (A,E); zeolite (B,F); zeolite
plus iron (C,G); iron (D,H). The black bar at left bottom in the first panel of each row represents 80 lm.
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with postmortems showing yellowing of the tissues and
enlarged organs in the peritoneum. Liver histology
showed damage to liver tissue in iron-treated mice
only. Extensive deposition of iron was seen in the
Kupffer cells in iron-treated mice, but much less iron
in the iron + zeolite subgroup.
Finally, there were differences in the uptake of iron
by the liver macrophage (Kupffer cell) system. The
number of iron-containing macrophages seen in
iron + zeolite sectioned liver was about double the
macrophage total counted in iron-treated mice, an indi-
cation of significantly more successful clearance of iron
by higher numbers of macrophages in mice cotreated
with zeolite (Fig. 6; right bar). This result supports the
Prussian blue histology depicted in Fig. 5, in which the
accumulation of iron was much less prevalent in sections
from the iron + zeolite treated mice (Fig. 5G) than in
the iron-treated mice (Fig. 5H). There were a small
number of lymphocytes in the histology slides from the
zeolite and iron + zeolite subgroups (not shown).
The immunostimulatory effects of zeolites are well
documented. Clinoptilolite has been shown to have an
immunostimulatory effect in mice [21,27]. In the first
of these studies, mice injected intraperitoneal with
clinoptilolite caused an increase in the number of peri-
toneal macrophages, a similar result to what we
observed (Fig. 6). In the latter study, micronized zeo-
lite was administered by gastric intubation to mice
injected with melanoma cells. The number of mela-
noma metastases and the degree of lipid peroxidation
decreased. The authors suggest a possible mechanism
for these results is an increased activation of macro-
phages and stimulants of the immune system. Other
studies have found that orally administered clinoptilo-
lite is a potent antioxidant [28] and does not alter
serum chemistry to any significant extent [29].
Cell death is crucial for normal development, home-
ostasis and the prevention of hyperproliferative dis-
eases such as cancer [30,31]. Iron is an important
contributor to cell damage and death in humans with
iron overload disease. Ferroptosis is a specific iron-
dependent form of nonapoptotic cell death, and it is
morphologically, biochemically and genetically distinct
from apoptosis, necrosis and autophagy [32]. Although
ferroptosis is characterized by lipid peroxidation and
reactive oxygen generation from iron Fenton chem-
istry, the precise role of iron remains unclear. It may
involve one or more iron-dependent enzymes function-
ing as part of a core oxidative lethal mechanism.
Many animal models of iron-induced cancers includ-
ing mesothelioma have been studied [5,6], and these
trials were typically longer than the present study. In
these trials, the only treatment considered was that of
the reference standard iron chelator deferoxamine.
However, having been used clinically for over four
decades, its effectiveness is limited by a demanding
therapeutic regimen of slow subcutaneous administra-
tion and poor plasma half-life that leads to poor com-
pliance [33,34].
Deferasirox (Novartis Pharma AG) represents a new
class of tridentate iron chelators, which can be given
as an oral daily dose. It has been in use since 2005,
but warnings about gastrointestinal haemorrhage and
kidney and liver failure were attached to its use follow-
ing a report of 1320 patient deaths by the Institute of
Safe Medical Practices in 2009. In contrast to chelators
with poor patient outcomes, zeolites are natural, inert
and nontoxic aluminosilicates, which are classified as
GRAS (Generally Regarded As Safe) by the US Food
and Drug Administration. One study [35] found that
clinoptilolite (the same zeolite used in our study) was
inert in the rat lung at 360 days. Others have shown
that clinoptilolite has no known carcinogenic effect
[15], and only very high doses (300 mgkg1) of clinop-
tilolite cause a focal storage type reaction in lung tis-
sue [36]. This concentration (300 mgkg1) is ten times
the amount used in our study.
The purpose of the present study was to examine
potential alternatives to current chelator treatments of
iron overload disorders, and the results suggest that
common zeolites may open a new treatment potential
for iron overload disorders.
This pilot study served as a prelude to a broader
mouse model study, using the same MexTAg299 h
strain to test the effectiveness of clinoptilolite to scav-
enge iron released from asbestos injected into the peri-
toneum, and thereby moderate the onset of
mesothelioma, which has been found to indeed be the
case (manuscript in preparation). The very promising
Fig. 6. Phagocytosed iron deposits in liver Kupffer cells in iron-
treated mice (left bar) and iron + zeolite treated mice (right bar).
The differences were analysed using an unpaired t-test, which
calculated the difference as significant (P < 0.0012). Errors as SD.
**indicates P < 0.01.
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findings from this asbestos/mesothelioma study rein-
force the importance of the present iron mouse model
study, as the sequestration of iron is one of the mecha-
nisms by which the moderation of mesothelioma has
been postulated in the asbestos mouse model.
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